B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)
- 1 August 2007
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (8) , S340-S341
- https://doi.org/10.1097/01.jto.0000283155.03863.e7